Acute promyelocytic leukemia current treatment algorithms.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML), characterized by a severe bleeding tendency.
• APL arises from the t(15;17) translocation, forming the PML-RARA fusion oncogene that inhibits myeloid differentiation.
• Historically, APL had a poor prognosis with no effective treatments prior to the 1970s.

Purpose of the Study:

• To review the historical evolution of acute promyelocytic leukemia (APL) therapy.
• To highlight key milestones in APL treatment development.
• To discuss current standard-of-care APL therapy, including treatment algorithms and management strategies.

Main Methods:

• Literature review of historical and contemporary APL treatment strategies.
• Analysis of key therapeutic advancements, including anthracyclines, all-trans retinoic acid (ATRA), and arsenic trioxide.
• Synthesis of current treatment guidelines and management recommendations for APL.

Main Results:

• Early treatments for APL were largely ineffective, leading to a rapid downhill course.
• The introduction of anthracyclines in 1973 and all-trans retinoic acid (ATRA) in the mid-1980s significantly improved response rates.
• Combinations of ATRA, chemotherapy, and arsenic trioxide have transformed APL into a highly curable disease.

Conclusions:

• APL therapy has progressed dramatically, shifting from a fatal diagnosis to a curable malignancy.
• Current standard-of-care integrates multiple agents to achieve high cure rates and minimize treatment-related mortality.
• Continued research and optimized treatment algorithms are essential for managing APL effectively.